Clinical Trial Update: Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC [Phase 3]

View source ↗

Summary

This is a Phase 3 study evaluating liposomal irinotecan with 5-fluorouracil as second-line therapy for esophageal squamous cell carcinoma; the trial is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Rui-hua Xu, MD, PhD | Conditions: Esophageal Cancer | Phase 3 | Status: NOT_YET_RECRUITING